Novel mechanism and compound for the treatment of metastatic cancers
Inventors: Bruce Zetter, Lijun Sun
Invention Types: Therapeutics
Research Areas: Oncology/Hematology
Keywords: For More Information Contact: Dietz, Ryan
While treatment regimens for non-metastatic cancers have improved dramatically in recent history, treatment of metastatic cancers remains difficult and expensive. Five year survival rates for patients with metastatic cancer are very low, and current treatment protocols have a low success rate. Current paradigms involve the use of specific, systemic classes of drugs (e.g. androgen deprivation therapy for the treatment of recurrent prostate cancer) until resistance develops, followed by non-specific drugs which target rapidly dividing cells, such as paclitaxel or cisplatin. These approaches may extend life by 2-5 years, depending on the specific cancer and treatment regimen, but complete remission is rare. Additionally, these drugs can cause severe cytotoxic effects in healthy tissue.|
Dr. Zetter’s and Dr. Sun’s teams have identified a novel therapeutic compound, OBD9, which can selectively impair highly aggressive, metastatic tumor cells through an unprecedented and novel biological mechanism, suggesting the potential for its use in cancers resistant to other chemotherapeutics. This potent anti- proliferative and pro-apoptotic activity was demonstrated on prostate and lung cancer cells while showing little or no toxicity to normal human epithelial cells. OBD-9 is active at low micromolar concentrations, allowing the compound high potency in addition to its apparent specificity for cancer cells. Additionally, OBD9 has been shown to be effective in combination therapies with other chemotherapeutics such as cisplatin, allowing it to enhance the efficacy of existing treatment regimens. OBD9’s distinct mechanism of action, high specificity for cancer cells, and strong anti-cancer effects make it an exciting potential therapeutic for the treatment of aggressive cancers and those resistant to currently available treatments.
• Treatment of highly aggressive, metastatic cancers such as prostate, lung, breast, colon, and pancreas
• Novel mechanism of action allows for use in highly resistant cancers or in combination therapies with platinum-based drugs or immunotherapy regimens
• Very high efficacy and low cytotoxicity compared to other generalized chemotherapeutics used to treat metastatic cancers
• High solubility allows for oral or intravenous administration
Sponsored research or exclusive license
IPStatus: Pat. Pend.